MOTS-c for Diabetes: What the Evidence Shows
What human and animal studies show about MOTS-c for diabetes, how strong that evidence is, and what is still unproven.
- Strongest evidence
- Human RCT
- Human studies
- 25
- PubMed records, our ledger
- Animal studies
- 16
- PubMed records, our ledger
- Studies we summarised
- 5
- with an outcome for diabetes
Evidence for diabetes
Each row is an outcome related to diabetes from a published study, strongest design first. Animal and cell results are labelled and are not human results. User reports are not counted as evidence here.
| Outcome | Result | Study type | Source |
|---|---|---|---|
| Circulating MOTS-c with metformin | No significant change in circulating MOTS-c after 24 weeks of chemotherapy with or without metformin. | Human RCT | Aging 2022, PMID 36490309 |
| MOTS-c response to lipid and insulin | Intralipid raised plasma MOTS-c in controls and PCOS subjects; insulin blunted the response. | Human observational | Clinical endocrinology 2019, PMID 31066084 |
| Hyperglycemia and islet inflammation | MOTS-c ameliorated hyperglycemia and reduced islet-infiltrating immune cells in NOD mice. | Animal · mouse (plus human serum) (not a human result) | Cell reports 2021, PMID 34320351 |
| Serum MOTS-c in type 1 diabetes | Patients with type 1 diabetes had lower serum MOTS-c than healthy controls. | Animal · mouse (plus human serum) (not a human result) | Cell reports 2021, PMID 34320351 |
| Ovariectomy-induced obesity | MOTS-c prevented ovariectomy-induced obesity and insulin resistance in mice. | Animal · mouse (not a human result) | Journal of molecular medicine 2019, PMID 30725119 |
| Obesity and insulin resistance | MOTS-c treatment prevented age-dependent and high-fat-diet-induced insulin resistance and diet-induced obesity in mice. | Animal · mouse (not a human result) | Cell metabolism 2015, PMID 25738459 |
PubMed records for MOTS-c and diabetes: 25 human, 16 animal (search counts, not studies we reviewed). Grades follow our .
How strong is it?
A human randomized trial outweighs any number of animal studies. Animal and cell results show a mechanism worth testing, not that it works in people.
What diabetes and insulin resistance mean
MedlinePlus defines diabetes as a disease in which blood glucose is too high because the body cannot make insulin, cannot use it well, or both.[6]
What the MOTS-c studies actually show
A PubMed search for MOTS-c with diabetes or insulin-resistance terms found 25 human-only and 16 animal papers, including 3 tagged randomized trials.
Calculated from pubmed query ("MOTS-c"[tiab] OR MOTSc[tiab]) AND (diabet*[tiab] OR "insulin resistance"[tiab] OR "insulin sensitivity"[tiab] OR glycemic[tiab] OR glycaemic[tiab] OR HbA1c[tiab] OR hyperglyc*[tiab] OR "glucose tolerance"[tiab]); date 2026-10-02; human filter count 44; human only count 25; animal filter count 16; randomized filter count 3. Formula: counts as recorded in the goals.json ledger (PubMed [tiab] query with the human, animal and RCT filters shown)
In mice, MOTS-c treatment prevented age-related and high-fat-diet insulin resistance and diet-induced obesity.[5]
In a mouse model of autoimmune diabetes, MOTS-c eased hyperglycemia and reduced immune cells in the islets.[3]
The same paper found that people with type 1 diabetes had a lower serum MOTS-c level than healthy controls. That is a level, not a treatment result.[3]
In women with PCOS and in controls, an intralipid infusion raised plasma MOTS-c, and an insulin infusion blunted that response.[2]
In a randomized trial of neoadjuvant chemotherapy/trastuzumab with or without daily metformin, circulating MOTS-c did not significantly change over 24 weeks.[1]
Anti-doping status
MOTS-c appears by name in WADA's list, in the group of AMPK activators.[7]
Other peptides people research for diabetes
All peptides for diabetes, comparedCommon questions
Does MOTS-c help with diabetes?
The strongest study we summarise for diabetes is human rct evidence, across 5 studies with an outcome for diabetes. A trial result is not an approval; see the legal status.
Is MOTS-c approved for diabetes?
No. MOTS-c is not FDA approved for any use, including diabetes.
What is the best peptide for diabetes?
There is no single answer. Our diabetes overview compares each candidate by evidence grade and legal status rather than by popularity.
Does MOTS-c help with diabetes or insulin resistance?
Only in mice. The human papers cited measured the body's own MOTS-c levels, and none gave MOTS-c to people with diabetes.[5]
Can MOTS-c lower blood sugar?
In a mouse autoimmune diabetes model it eased hyperglycemia. No human blood sugar trial is cited.[3]
Is MOTS-c allowed in sport?
WADA's list names MOTS-c among AMPK activators.[7]
More on MOTS-c
Sources
- 1Circulating levels of MOTS-c in patients with breast cancer treated with metformin.Aging · 2022PMID 36490309Accessed 2 Oct 2026
- 2Lipids and insulin regulate mitochondrial-derived peptide (MOTS-c) in PCOS and healthy subjects.Clinical endocrinology · 2019PMID 31066084Accessed 2 Oct 2026
- 3Mitochondrial-encoded MOTS-c prevents pancreatic islet destruction in autoimmune diabetes.Cell reports · 2021PMID 34320351Accessed 2 Oct 2026
- 4MOTS-c peptide regulates adipose homeostasis to prevent ovariectomy-induced metabolic dysfunction.Journal of molecular medicine (Berlin, Germany) · 2019PMID 30725119Accessed 2 Oct 2026
- 5The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance.Cell metabolism · 2015PMID 25738459Accessed 2 Oct 2026
- 6Official web pageOfficial web page · web page
- 7World Anti-Doping Code International Standard Prohibited List 2026 (in effect 1 January 2026)World Anti-Doping Agency · 2026wada-ama.orgAccessed 2 Oct 2026
Found an error? Report a correction.